Journal
GLP-1 provider journal
Released: Last reviewed:
The GLP1ProviderFinder journal has 225 articles on GLP-1 telehealth prices, providers, regulation, coverage, state availability and clinical questions; price figures in older articles carry dated notices, and current prices are in the price database read October 15, 2026.
New this month
Counterfeit Ozempic Charges and Brand GLP-1 Channels
Two Indian nationals were charged over counterfeit Ozempic on Sept. 29, 2026. Which brand GLP-1 channels in our index name their pharmacy, and the checks.
GLP-1 Provider Matchups Within $20 a Month (Oct 2026)
Of 110 GLP-1 provider head-to-heads with an October 15, 2026 price verdict, 15 sit within $20 a month. The pairs, the yearly math, and what decides them.
Prices, costs and the market
The Teaser Index: Advertised vs True GLP-1 Prices Across 37
Original analysis from our database: the gap between the price in the ad and the all-in figure you actually pay. The five mechanisms that create the gap, the widest spreads in the market measured in words — TMates' 78%, Found's 71%, ShedRx's 45% — the programs where the ad and the checkout match, and the one-line defense.
Certificates of Analysis for Compounded GLP-1s
The COA is the document that converts 'trust us' into data: identity, potency, sterility, and endotoxin results for a specific lot, ideally from an independent laboratory. What each section means, the reading checklist, and what a refusal to provide one tells you.
Compounded Semaglutide Prices at Maintenance (Oct 2026)
What compounded semaglutide costs at the maintenance dose in 2026, how it compares with $349 Wegovy pens and $149 oral Wegovy, and the checks before you pay.
Cheapest Compounded Tirzepatide With No Annual Commitment
Not willing to pay a year upfront? Month-to-month compounded tirzepatide prices in 2026 (NexLife $129 from Nov 6, Eden $129 on Oct 15) and why $125 deals required a full year.
Compounded Tirzepatide Prices at Maintenance (Oct 2026)
What compounded tirzepatide costs at the maintenance dose in 2026, how it compares with $449 Zepbound vials, the legal ground, and seven checks before paying.
Why Compounded GLP-1s Come With B12 (or Glycine)
Compounded semaglutide and tirzepatide routinely ship blended with vitamin B12, or with glycine and B6 — and the marketing implies energy and enhanced results. The real reasons are duller: formulation, tolerability claims, and the post-shortage regulatory logic of not being an exact copy. What each additive plausibly does, and the claim with no evidence behind it.
Beyond-Use Dates: Why Compounded GLP-1s Expire in Weeks
The date on a compounded vial isn't a manufacturer expiration — it's a beyond-use date assigned under USP standards, typically weeks out, reflecting sterility and stability limits of pharmacy-prepared sterile products. What BUDs mean, why they're short, and why the discard rule is absolute.
Compounded Tirzepatide vs Zepbound in 2026
Zepbound vials cost $299–$449 a month through LillyDirect with a 45-day refill rule; compounded tirzepatide runs $125–$179 at the credible low end. The full arithmetic: what the $1,800–$3,900 annual spread buys, when each path wins, the insurance and Medicare routes that beat both, and the one calendar rule that can double a brand month.
Flat vs Dose-Tiered Tirzepatide Pricing
Tirzepatide dosing is designed to escalate — which makes the pricing structure, flat or dose-tiered, worth more than the sticker. The titration schedule in months, why a cheaper tiered start loses to a flatter number by mid-year, the questions that expose a tier before you buy, and how our database records each structure.
The True 12-Month Cost of Every GLP-1 Path
What a year of GLP-1 treatment costs: 12-month totals for compounded and brand programs, with prices dated and the October 15, 2026 re-read in the notice.
The Cancellation Policy Census
The exit clause is the price nobody reads: this census records what our files establish about each tracked program's cancellation, refund, and pause terms — flat-rate simplicity, prepaid refund clauses, membership seams, promo-lock forfeitures — and marks 'unknown' honestly where captures don't reach, with the exact questions that fill each blank.
What the First 90 Days on a GLP-1 Actually Cost
Startup economics differ from steady state: brand titration rungs cost less, intro offers front-load savings, compounded flat rates don't move, and one-time costs cluster early. The honest 90-day budgets for every lane, and the traps in month four.
The GLP-1 Gray Market: What Buying From Peptide Sites and
Research-chemical vials, group buys, and forum-sourced 'tirz' occupy the space below the legal market — and every step of that supply chain removes a protection: identity, purity, sterility, dosing infrastructure, legal standing, recourse. The clear-eyed risk map, and the legal lane that removes the motive.
The 2026 GLP-1 Market Ledger
Original from our records: the year the compounded market consolidated in public. Hims and Ro's brand-only pivots, the sub-$100 figures that failed verification and stayed out, thirteen programs entering the tracked universe in one August, the December price cut that reset the brand floor, and what the churn pattern predicts.
The GLP-1 Market Report: August 2026
The quarterly-style state of the market: computed category leaders and the margins behind them, the three dated windows closing this year, the regulatory docket that could reshape the compounded lane, verification-status distribution across all 37 tracked programs, and the watch-list for the next report.
Membership Fees in GLP-1 Programs
A membership fee is a price that ships no medication — $75 to $149 a month across the programs that charge one, $900 to $1,600 a year of structural cost before a single vial. The live cases from our database (Zealthy's $135, Mochi's $79, LifeMD's fee-inside figure), the zero-fee programs that prove the fee is a choice, and the one-line question that surfaces every hidden membership.
The GLP-1 Price-Change Ledger
A running, dated record of compounded and brand GLP-1 price movements in 2026: NexLife's standing prices, Eden's October cut, the semaglutide floor changes, NovoCare's introductory window, and the LillyDirect refill condition — every entry dated and status-labeled.
The GLP-1 Price Wars, 2021–2026: How $1,349 Became $99
Five years compressed the most expensive drug launch in memory into a functioning competitive market: launch lists near $1,350, the shortage-era compounding boom, LillyDirect's vial gambit and December 2025 restructuring, NovoCare's counterattack, the Hims settlement, and the compounded floor's slide to $99. The full history, with every date that still matters.
Refund and Cancellation Terms Across GLP-1 Programs
Every program's price page shows what joining costs; the terms page shows what leaving costs, and the spread is wider. The structural patterns across our database's cancellation fields — notice periods, prepaid clawbacks, separately-billing memberships, quarterly cycles — what each pattern means in dollars, and the four screenshots to take on signup day.
Who Still Sells Compounded Tirzepatide in 2026
Mass compounding of tirzepatide ended in early 2025; the 503A individual-patient lane remains. Who operates in it, on what evidence, from our 44-program index.
GLP-1 Refunds and Chargebacks
The credit card dispute is this market's last-resort protection — strongest for unauthorized and post-cancellation charges, real for paid-never-shipped, weak for buyer's remorse. The evidence pack, the sequence (merchant first), the timelines, and the honest limits.
GLP-1 Scam Red Flags: The Eight Tells That End the
Below the discount market sits the fraud market, and it telegraphs itself: no prescription required, crypto-only payment, prices under the floor of possibility, counterfeit brand pens, research-chemical fig leaves. The eight tells, why each one is disqualifying, and the two-minute legitimacy check.
The GLP-1 Telehealth Intake
Between checkout and prescription sits the intake — an async questionnaire or video visit whose questions exist for your safety, not the program's paperwork. What legitimate intakes ask, why honesty on five items is non-negotiable, and the rubber-stamp signs that grade a program in one screen.
How Much Does Semaglutide Cost in 2026? Every Channel
The complete semaglutide price map: $25 copays where covered, the $99–$139 compounded floor, the $149 approved oral tablet that squeezes it, $349 pens with a $199 introduction — and the routing that picks your lane in three questions.
How Much Does Tirzepatide Cost in 2026? Every Channel
The complete tirzepatide price map: $25–$50 insured copays where covered, $125–$179 credible compounded, $299–$449 brand vials by dose with the 45-day rule, and the reseller tier above — with the routing logic that picks your channel in three questions.
How to Cancel a GLP-1 Subscription Cleanly
Cancellation is a documentation exercise: find the actual mechanism, act before the renewal cutoff, capture written confirmation, and verify the next statement. The general protocol that works everywhere, plus the retention-offer math worth running before you say no.
How to Read a Compounded GLP-1 Label
The vial label is a dense little document that answers every dosing and safety question — if you know its seven fields: drug and salt form, concentration, BUD, storage, lot, pharmacy identity, and directions. The walkthrough, and the cross-checks that catch mistakes before injection.
Switching GLP-1 Providers Without a Gap
Provider-switching is routine — promo expirations, price drops, and service failures all justify it — and it has exactly three failure modes: a medication gap, an overlap double-dose, and the old subscription billing on. The clean-handoff protocol, step by step.
The 45-Day Refill Window: The Most Expensive Calendar Rule
LillyDirect's $299–$449 Zepbound vial pricing is conditional on refilling inside a 45-day window — miss it and the discounted self-pay structure resets. How the clock actually runs, what an off-window month costs against the $1,086-plus pen list price, the four ways people miss it by accident, and the calendar system that protects the discount.
Mounjaro vs Ozempic: The Diabetes Head-to-Head SURPASS-2
For type 2 diabetes the comparison has trial data: SURPASS-2 tested tirzepatide against semaglutide 1 mg head-to-head — tirzepatide won on A1c and weight at every dose. What the result means, its 1-mg asterisk, and how coverage actually decides this choice.
Mounjaro vs Zepbound: One Tirzepatide
Lilly's tirzepatide wears two names: Mounjaro for type 2 diabetes, Zepbound for weight management and sleep apnea — same molecule, same 2.5-to-15 mg ladder. The differences that matter: indications, insurance logic, and the fact that the $299–$449 vial program is Zepbound-only.
Oral Semaglutide in 2026: The $149 Wegovy Tablet
FDA-approved semaglutide now comes as a daily tablet from $149 a month at NovoCare — the cheapest approved GLP-1 in existence — with strict absorption rules that decide whether it works. How the tablet compares to the pen, what the oral trial program showed, and the honest difference between this and the compounded sublingual products advertised at $99.
Ozempic vs Wegovy: Same Molecule, Different Labels
Both are Novo Nordisk's semaglutide; the differences are indication (diabetes vs obesity plus cardiovascular), dose ceilings (2 mg vs 2.4 and the newer 7.2 tier), insurance treatment, and cash channels. The practical comparison that ends the most common naming confusion in the class.
Rybelsus vs Oral Wegovy: Two Semaglutide Tablets
Both are oral semaglutide with the same brutal empty-stomach ritual — but Rybelsus carries the diabetes label at 7–14 mg while oral Wegovy carries the weight label at higher doses with ~15% trial results. The distinction, the OASIS data, and which tablet answers which question.
Saxenda vs Wegovy: What the Older Daily Drug Still Answers
Liraglutide walked so semaglutide could run: daily injections, ~8% average loss in SCALE versus 14.9% in STEP — yet generics arriving since 2024, pediatric-label history, and formulary quirks keep Saxenda-class questions alive. The honest comparison and the niche that remains.
Start Price vs Maintenance Price
Every misleading GLP-1 ad runs the same play: quote the price of a month you'll leave against a competitor's price for the months you'll live in. The four variants of the trick — starter-dose pricing, first-month promos, microdose tiers, and funnel-gated maintenance — with a live example of each from our own database, and the two-question test that defeats all four.
Switching From Semaglutide to Tirzepatide
There is no validated conversion chart — prescribers switch by stopping one, starting the other at or near its starting dose, and re-titrating. Why the restart is the method, what the trials say you can expect from the move, the washout question, and the $40–$270 monthly price change that comes with it.
The True First-Year Cost of Tirzepatide, Month by Month
Not a sticker — a calendar. The twelve months of a standard tirzepatide first year priced at every decision point: titration months, the maintenance stretch, the promo reversion, the missed-window scenario, and the honest annual totals across compounded floors, market median, and the brand pathway.
Tirzepatide 12-Month Prepaid Plans
Prepaid plans buy a real discount with real risk: your money concentrates in one company, one pharmacy pathway, and one regulatory moment. The current prepaid ladder from the database, what the discount is actually pricing, the five questions that separate a good prepaid from a trap, and the 2026-specific reason to read refund terms before wiring a year.
Tirzepatide vs Semaglutide in 2026
In the only head-to-head trial (SURMOUNT-5), tirzepatide beat semaglutide 20.2% to 13.7% average weight loss at 72 weeks. Semaglutide costs $40–$270 less a month at every tier. The mechanism, the trial read honestly, the full price ladders, cost per percentage point, and how a clinician actually chooses.
How to Verify a GLP-1 Compounding Pharmacy's License
The complete verification workflow for any compounding pharmacy filling tirzepatide or semaglutide: getting the legal name, running the home-state license, checking the nonresident license in your state, confirming 503A/503B status on FDA's list, and reading the inspection record — with the red flags that end the check early.
Semaglutide Clinic Near Me vs Telehealth
Local med-spa and clinic GLP-1 programs commonly price at a multiple of the telehealth floors — and sometimes earn it. What in-person genuinely adds (labs, body composition, hands-on titration), what it usually doesn't (a different medication), the questions that expose a markup wearing a lab coat, and when local actually wins.
Why Compliant Compounded Tirzepatide Costs $249–$549
The compounded tirzepatide market's compliant core runs roughly $249 to $549 all-in, with independent tracking putting the month-to-month average near $332. What that money buys — licensed compounding, testing, clinical oversight, cold-chain shipping — line by line, why the floor exists, and how to read a price far below it as the signal it is.
Zepbound Vial Prices by Dose in 2026
Every Zepbound self-pay price by dose — $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 to 15 mg — plus the 45-day refill rule, the $599–$1,049 off-window penalty, vials versus KwikPen, and the annual math at each dose.
Zepbound vs Wegovy: The Head-to-Head Trial
The only direct comparison that exists — SURMOUNT-5's 20.2% vs 13.7% at 72 weeks — plus everything the single number leaves out: SELECT's cardiovascular indication, the sleep-apnea door, oral options, and cash ladders of $299–$449 versus $149–$399.
Provider reviews and head-to-heads
Amble Health Review 2026: A $300 Tirzepatide-Only Row
Amble Health appears in our database as a single provider-stated fact: compounded tirzepatide at $300, no semaglutide. The shortest honest review we publish — placement, the questions that would fill the row, and what a thin public record should mean to a buyer.
bmiMD Review 2026: Flat-Rate Ladder on the August Record
bmiMD holds the semaglutide crown on our computed rankings — $129 month-to-month down to $99 on twelve months, same price at every dose — and ties the tirzepatide twelve-month floor at $139. The audit: the term-ladder fine print, the named-pharmacy claim to confirm, and exactly where it wins and loses.
Care Bare Rx Review 2026: $199 Flat
Care Bare Rx runs the simplest sentence after Henry's: $199 a month, semaglutide or tirzepatide, month-to-month, ad matching checkout — with a lighter clinical model our records flag for refill-cadence and prescriber-access questions. Short structure, short review.
Direct Meds Review 2026: Format-Priced From $249 to $399
Direct Meds prices by format — semaglutide from $249 sublingual to $297 injection, tirzepatide from $299 to $399 — with 'billed every month, 0% off' first-party clarity and no plan gymnastics. The audit: what format pricing means, the sublingual caveat, and where honest-but-high lands.
Eden Review 2026: The Widest Footprint
Eden's structural story is unique: roughly fifty-state coverage and its own compounding pharmacy — Contigo, acquired August 2025 — and, as of October 15, 2026, published flat prices of $129 a month for tirzepatide and $99 for semaglutide with no membership fee. The audit of vertical integration, and what the new prices change.
Empower Pharmacy and Your GLP-1
Empower Pharmacy, a large Houston compounding operation, received FDA warning letter 738238 on September 18, 2026 over compounded tirzepatide and semaglutide products. What the letter says, and the five checks to run on any pharmacy: licenses, FDA records, the 503A/503B distinction, accreditation, and the COA question.
Enhance MD Review 2026: Bundled Metabolic Programs From $212
Enhance MD sells tiers, not vials: 'GLP-1 Core' semaglutide at $212 ($112 first month), tirzepatide 'Advanced' at $280, combo 'Elite' at $322, microdosed tirzepatide at $169 — each bundling provider care and six-month metabolic labs. The audit prices the program as a program.
Fifty 410 Review 2026: The Famous $133 That Isn't a Price
Fifty 410's $133 tirzepatide is one of the market's most-quoted numbers — and it's a starting figure with no published maintenance rate, the textbook case behind our unrankable rule. The review of a number, and of the rule it justified.
Found Review 2026: $359 Month to Month or $239 on 12 Months
Found's compounded tirzepatide cash price, read October 15, 2026: $219 the first month, then $359 per 28-day cycle month to month, or $309, $289 and $239 on 3-, 6- and 12-month terms. Plus an insurance track, and one caveat its ads underplay: the clinician may prescribe something other than a GLP-1. The audit of the structure and who it fits.
Fridays Review 2026: $175 Semaglutide, $359 Tirzepatide
Fridays runs a split book: semaglutide at $175 — inside the competitive band — and tirzepatide at $359, upper-shelf territory. The short audit of a program whose two molecules argue different cases.
Gala GLP-1 Review 2026: The $149–$199 Range
Gala publishes a range rather than a rate — $179 standard 'all doses,' $199 on a three-month plan, $149 microdosing — across an all-fifty-state claim. The audit: what each figure means, the microdosing tier read against the evidence, and the one enrollment question that sets your actual number.
Hallandale Pharmacy and Your GLP-1
Hallandale Pharmacy is a Florida compounding pharmacy people often ask about for GLP-1 prescriptions. Rather than a puff piece, here's the five-check vetting process any buyer can run in fifteen minutes — license lookups, FDA inspection records, 503A status, accreditation, and the COA request — using Hallandale as the worked example.
HealthRX Review 2026: $99 Semaglutide With a Term Ladder
HealthRX co-holds the $99 twelve-month semaglutide floor and posts $179 twelve-month tirzepatide — flat at every dose, billed monthly — with one structural quirk: no month-to-month plan exists, so the shortest commitment is three months at $133/$209. The audit of what that shape means and where it ranks.
Henry Meds Review 2026: The $179 Benchmark
Henry Meds was the market's $179 flat reference point. On October 15, 2026 its GLP-1 page says pricing varies by plan and dosing and "starts at $179/month," with no molecule-specific price. The audit: what the $179 includes, the unnamed-pharmacy gap, the corrected price history, and who now prints lower prices.
Henry Meds vs bmiMD: The Flat-Rate Flagship Against the
The two most-recommended budget programs solve the same problem differently: Henry's one-price-forever $179 simplicity versus bmiMD's four-rung ladder from $129/$179 down to $99/$139. The structural comparison, molecule by molecule, with the tie-breakers that actually decide.
Hims & Hers GLP-1 Review 2026
Since the March 9, 2026 Novo settlement, Hims & Hers sells brand GLP-1s only — Wegovy $299, oral Wegovy $249, Zepbound $399 — atop a $149 membership, for true all-ins of $448–$548. The audit of what the platform adds, and the direct-channel math it must beat.
Hims vs Ro in 2026: Two Post-Compounded Platforms
Both exited the compounded era into brand-only models — Hims as a membership storefront ($448–$548 all-in), Ro as an insurance concierge with a cash fallback ($448–$598). Same products, opposite theses; the comparison that routes by coverage status.
Ivim Health Review 2026: The $75 Program-Fee Model
Ivim's weight-loss page, read October 15, 2026, lists compounded tirzepatide "starting at $117/mo + $75/mo Program Fee" and semaglutide "starting at $65/mo"; maintenance-dose prices are not printed. The audit of the program-fee model and the questions that decide it.
Lavender Sky Health Review 2026: $174/$352, the Fridays Twin
Lavender Sky mirrors the split-book pattern almost to the dollar: $174 semaglutide in the competitive band, $352 tirzepatide on the upper shelf. The short audit and the tie-breaker questions against its twin.
LifeMD Review 2026: Brand GLP-1s Plus a $149 Program Fee
LifeMD's weight-management page, read October 15, 2026, prints no compounded price; it sells Zepbound vials from $299 and Wegovy pens from $199, each plus a $149 monthly program and provider fee. Our earlier $597/$348 compounded record, and what full-service telehealth costs.
LillyDirect Review 2026: The Benchmark Itself
LillyDirect's Zepbound vial program — $299/$399/$449 by dose, 45-day refill rule, no subscription — is the figure every compounded price on this site answers to. The manufacturer's channel gets the same audit: strengths, the calendar trap, and who should pay the benchmark.
LumiMeds Review 2026: $125 Tirzepatide on a Prepaid Year
LumiMeds advertised compounded tirzepatide at $125 a month on a $1,500 upfront twelve-month plan and $140 on six months, with no semaglutide and no month-to-month rate, on a status honestly labeled: reported from a community-sourced capture, first-party verification pending. The audit of a low price on thin evidence.
Luvo Health Review 2026: 52-Week Math
Luvo publishes term totals in weeks — $2,327 for a year of semaglutide ($194/mo equivalent), $3,497 tirzepatide ($291) — with $249/$339 four-week no-commitment rates, four named dispensing pharmacies, and, per an August 2026 audit, no stated 503A/B status or third-party testing claim. The full decode.
MEDVi Review 2026: $299/$399
MEDVi's provider-stated rates — $299 semaglutide, $399 tirzepatide — mirror Remedy's altitude without a public service bundle to explain them. The short audit and the three questions that would justify, or fail to justify, the premium.
Mochi Health Review 2026: Per-Dose Pricing for the Most
Mochi bundles the most clinical programming in the compounded market — dietitians, labs, structured curriculum — across only ~10 states. Its weight-loss page (read October 15, 2026) prints no compounded price; its own blog describes per-dose pricing of $90-$199 for tirzepatide and $60-$99 for semaglutide plus membership. The audit: what the premium buys and who it fits.
Which Pharmacies Fill NexLife Prescriptions? The Three
NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA). How to check each one's license and FDA record yourself, and the question to ask at intake: which one fills your prescription?
NexLife Tirzepatide Review 2026
NexLife's compounded tirzepatide is $129 a month on its monthly plan and $115 a month on its 12-month plan, the same price at every dose with no membership (plan pages read November 6, 2026). What is included, the three named 503A pharmacies, cancellation terms, how it compares with Eden, Henry Meds and bmiMD, and what to verify before enrolling.
Noom Med Review 2026: A Microdose GLP-1 Program Attached to
Noom Med now sells a microdose compounded GLP-1 program on the behavior-change app that made the brand: from $79 for the first period, then $179 a month (Noom's page, read October 15, 2026). The audit: what the app layer is worth, what microdosing means, and the psychology-plus-pharmacology case read honestly.
NovoCare Review 2026: The Semaglutide Counter
NovoCare is the semaglutide benchmark: Wegovy pens at $349 ($399 for the 7.2 mg tier), a $199 introduction on the first two starter fills through 2026, and oral Wegovy from $149. The manufacturer channel audited — including the tier fine print the headlines skip.
Oak Longevity Review 2026: The Quiet $133 That Almost Leads
Oak Longevity review: $133 month-to-month compounded semaglutide on our August 2026 record. Its site returned errors on October 15, so the figure is not re-read.
OrderlyMeds Review 2026: $149 Semaglutide That Competes
OrderlyMeds states its prices and they hold at checkout: $149 semaglutide — inside the value cluster — and $299 tirzepatide, double the flat tier. A split-verdict review: where the semaglutide number earns a shortlist spot, and the brand comparison the tirzepatide number walks into.
Remedy Meds Review 2026: The $399 Question a Forbes
Remedy Meds priced compounded tirzepatide at $399 and semaglutide at $299 on our August 2026 record — prominent, and not among the cheapest. The short audit: what the premium would need to buy, and the brand math at this altitude.
Ro Review 2026: The Insurance Concierge That Earns Its
Ro's 2026 model is brand medication plus the market's best coverage concierge — benefits checks, prior authorizations, appeals — which wins our 'best with insurance' category outright. Its cash all-ins of roughly $448–$598 are another story. Both halves, audited.
ShedRx Review 2026: Four Formats
ShedRx runs the market's widest format menu — injections, lozenges, drops, oral tablets — with tirzepatide listed "as low as $239/mo" on October 15, 2026 (July 2026 captures: start near $199, maintenance near $289), semaglutide injection from $249, and a 30%-off first month via affiliate links. The audit of the menu, the spread, and the promo plumbing.
SkinnyRx Review 2026: $199/$299
SkinnyRx keeps it stated: $199 semaglutide, $299 tirzepatide, provider-stated, with the advertised price surviving to checkout. A short review for a legible program — where it lands, what the premium over the floor buys, and the one question left.
Sprout Health Review 2026
Sprout's homepage, read October 15, 2026: compounded tirzepatide $199 per 4 weeks or $149 a month on a 12-month plan billed $1,788 up front; semaglutide $149 per 4 weeks or $99 a month ($1,188 up front); same price at any dose. Plus the brand prices captured earlier, and what to confirm before paying.
Strut Health Review 2026: The $99 Entry That Can't Be Ranked
Strut advertised a $99 sublingual and $149 injectable semaglutide entry (July 2026) and, on October 15, 2026, tirzepatide "as low as $149" for a 30-day supply — lowest-dose or plan-dependent starting prices with no published maintenance rate, plus a tirzepatide lozenge gated behind injectable failure. Why our methodology records it without ranking it, and the questions that would change that.
Synergy Rx Review 2026: '$199 Starting' Under a Promo Banner
Synergy Rx advertises injectable semaglutide 'starting at $199' and tirzepatide at $349 beneath a live '2026 Promo Applied' banner and $100 welcome credit — classic promo-plus-start anchoring across an all-fifty-state claim with advertised named pharmacies. The decode and the enrollment questions.
TMates Review 2026: The $158 Headline and the 78% Spread
TMates advertises from $158 a month — the compounded semaglutide twelve-month rate — while month-to-month runs $249, and tirzepatide runs $167 committed against $297 monthly, the widest spread in our Teaser Index. The audit of what's included, and who the committed rates genuinely fit.
Yucca Health Review 2026: The $146 'For Life' Promo, Decoded
Yucca advertises the market's catchiest offer — '$146/mo for life' semaglutide under promo code YUCCA4LIFE — and the fine print does real work: new-patient six-month-plan entry rate, tirzepatide at $258, full pricing gated behind intake, pharmacies unnamed. The decode, the questions, and where it actually ranks.
Regulation, coverage and insurance
503A vs 503B: The Two Kinds of Compounding Pharmacy
Every compounded GLP-1 comes from one of two legal categories — 503A patient-specific pharmacies under state-board oversight, or 503B outsourcing facilities under FDA CGMP — and 2026's rules treat them very differently. The plain-English explainer this site's other pages lean on.
If the FDA Finalizes the 503B Exclusion
FDA proposed not to put tirzepatide or semaglutide on the 503B bulks list; no final decision as of Oct. 15, 2026. What a final rule would change for you.
Best GLP-1 Program With Insurance in 2026
With commercial coverage, brand Zepbound or Wegovy at a $25 copay beats every cash program in existence. How coverage actually gets used: the benefits check, the prior authorization, the appeal, Ro's concierge, the manufacturer savings cards, and Medicare's $50 GLP-1 bridge.
CagriSema: Novo's Next Act
Semaglutide plus cagrilintide — an amylin analog — is Novo's answer to tirzepatide: REDEFINE-1 reported roughly 22.7% average loss at 68 weeks, short of the company's own 25% target but ahead of anything semaglutide achieves alone. What the combination is, the timeline, and the compounded warning that already applies.
Buying Semaglutide From Canada
The Canadian-pharmacy route made a kind of sense at $1,300 US list prices. It makes much less at today's $149–$349 domestic channels — and the legal ground (personal importation is generally not permitted) and the documented counterfeit-Ozempic incidents haven't improved. The rules, the risks, and the honest comparison.
The CMS BALANCE Model, Explained
BALANCE explained: a CMS model for Medicaid GLP-1 coverage at negotiated prices, rolling state enrollment to Jan. 1, 2027, and its Medicare status in 2027.
The Compounded GLP-1 Enforcement Record
From the 2025 warning-letter wave through the February 2026 enforcement announcement, the March 3 thirty-letter action, the April 30 proposal to strike semaglutide and tirzepatide from the 503B bulks list, and the June 8 wave that named companies for hiding their pharmacies — the dated record, the specific violations, and the buyer checklist that falls out of it.
Appealing a GLP-1 Denial: The Letter
Denials are the system's first offer, not its final answer: internal appeals overturn a large share, external review exists by law when they don't, and the winning letter is documentation plus the plan's own criteria quoted back. The complete playbook, level by level.
The GLP-1 Insurance Doors
Coverage follows the diagnosis, not the molecule. The six doors — type 2 diabetes, weight management, cardiovascular risk, sleep apnea, chronic kidney disease, and MASH — which drug opens each, what the prior authorization asks for, and why the indication doors work even where weight-loss coverage doesn't.
Medicaid and GLP-1s: The State-by-State Reality
Which state Medicaid programs cover GLP-1s for weight loss in 2026, which ended coverage (Rhode Island on Oct. 1, 2026) and what other indications open.
Medicare and GLP-1s in 2026
Medicare and GLP-1s in 2026: the $50 Medicare GLP-1 Bridge (extended through Dec. 31, 2027), who is eligible, who is not, and what Part D plans cover.
The GLP-1 Pipeline, August 2026
The tracker: retatrutide's ~24% triple-agonist ceiling, CagriSema's ~23% and its expectations problem, orforglipron's ritual-free ~12% pill, survodutide's liver bet, amylin newcomers — with approval status, the no-legal-lane warning, and the only advice that survives every readout: treat now, switch later.
The GLP-1 Prior Authorization, Done Right the First Time
Most PA denials are documentation failures, not coverage failures: missing BMI history, uncoded comorbidities, absent step-therapy records. The complete package that approves — what plans actually check, the timeline, and the prescriber-office choreography that makes it happen.
GoodRx and GLP-1s: Where Discount Cards Actually Help
Discount cards barely dent brand GLP-1 prices — the manufacturer programs (LillyDirect's $299–$449, NovoCare's $149–$349, the $25 savings cards) are the real levers, and compounded programs are flat cash prices a coupon can't touch. Where GoodRx genuinely earns its place: the adjunct prescriptions around your GLP-1.
HSA and FSA for GLP-1s: What's Eligible
Prescription GLP-1s — brand or compounded — are generally HSA/FSA-eligible as prescribed medications, which turns pre-tax dollars into an effective 20–35% discount on every figure this site tracks. The eligibility logic, the Letter of Medical Necessity for cautious administrators, what's excluded, and the FSA deadline math on prepaid plans.
Is Compounded Tirzepatide Legal in 2026? The Complete Status
Yes — through one narrow lane: patient-specific 503A prescriptions under documented clinical need. The full dated timeline: shortage resolved December 19, 2024, grace periods ended spring 2025, 503B bulk compounding over March 19 2025, FDA's April 2026 proposal, 730+ adverse-event reports, Lilly's litigation, and exactly what stays legal for the patient.
Generic Liraglutide: The Class's First Real Generic
Since 2024, generic liraglutide has given the GLP-1 class its first true generic lane — daily injections, ~8% SCALE-era results, prices that vary wildly by pharmacy. The honest guide to when the old drug's new price beats the new drugs' old prices.
Orforglipron: The Small-Molecule GLP-1 Pill
Lilly's orforglipron is the class's manufacturing revolution: a non-peptide small molecule taken as a normal pill — no injection, none of oral semaglutide's empty-stomach ritual — with 2025 phase-3 readouts around 12.4% in obesity. Why 'good not spectacular' might still change everything.
Retatrutide in 2026: The Triple Agonist's Real Science
Retatrutide searches are up 150% on trial results approaching 24% average weight loss — but the drug is not approved, not compoundable, and everything sold under its name today is gray-market research chemical. The phase 2 data read honestly, the timeline, and the bright line buyers keep crossing.
Survodutide: The Glucagon Dual Agonist Betting on the Liver
Boehringer's survodutide pairs GLP-1 with glucagon receptor agonism — phase-2 obesity results up to ~19%, and MASH data striking enough (improvement in up to ~83% of treated patients) to make the liver its headline. What the mechanism trades, and where the phase-3 program points.
State guides
GLP-1s in Alabama (2026): Who Ships Here
Alabama telehealth GLP-1 care requires a Alabama-licensed prescriber and a Alabama-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Alabama State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Alaska (2026): Who Ships Here
Alaska telehealth GLP-1 care requires a Alaska-licensed prescriber and a Alaska-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Alaska Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Arizona (2026): Who Ships Here
Arizona telehealth GLP-1 care requires a Arizona-licensed prescriber and a Arizona-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Arizona State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Arkansas (2026)
Arkansas telehealth GLP-1 care requires a Arkansas-licensed prescriber and a Arkansas-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Arkansas State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in California (2026)
California telehealth GLP-1 care requires two things most buyers never verify: a prescriber licensed in California and a pharmacy holding a California license. Which tracked programs serve the state, the one major program that historically hasn't, the verification lookups, and the price floors that apply here like everywhere.
GLP-1s in Colorado (2026)
Colorado telehealth GLP-1 care requires a Colorado-licensed prescriber and a Colorado-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Colorado State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Connecticut (2026)
Connecticut telehealth GLP-1 care requires a Connecticut-licensed prescriber and a Connecticut-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Connecticut Commission of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Delaware (2026)
Delaware telehealth GLP-1 care requires a Delaware-licensed prescriber and a Delaware-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Delaware Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Florida (2026): Who Ships Here
Florida telehealth GLP-1 care requires a Florida-licensed prescriber and a Florida-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Florida Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Georgia (2026): Who Ships Here
Georgia telehealth GLP-1 care requires a Georgia-licensed prescriber and a Georgia-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Georgia Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Hawaii (2026): Who Ships Here
Hawaii telehealth GLP-1 care requires a Hawaii-licensed prescriber and a Hawaii-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Hawaii Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Idaho (2026): Who Ships Here
Idaho telehealth GLP-1 care requires a Idaho-licensed prescriber and a Idaho-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Idaho Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Illinois (2026)
Illinois telehealth GLP-1 care requires a Illinois-licensed prescriber and a Illinois-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Illinois Department of Financial and Professional Regulation lookup, and the price floors that apply here like everywhere.
GLP-1s in Indiana (2026): Who Ships Here
Indiana telehealth GLP-1 care requires a Indiana-licensed prescriber and a Indiana-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Indiana Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Iowa (2026): Who Ships Here
Iowa telehealth GLP-1 care requires a Iowa-licensed prescriber and a Iowa-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Iowa Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Kansas (2026): Who Ships Here
Kansas telehealth GLP-1 care requires a Kansas-licensed prescriber and a Kansas-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Kansas Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Kentucky (2026)
Kentucky telehealth GLP-1 care requires a Kentucky-licensed prescriber and a Kentucky-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Kentucky Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Louisiana (2026)
Louisiana telehealth GLP-1 care requires a Louisiana-licensed prescriber and a Louisiana-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Louisiana Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Maine (2026): Who Ships Here
Maine telehealth GLP-1 care requires a Maine-licensed prescriber and a Maine-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Maine Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Maryland (2026)
Maryland telehealth GLP-1 care requires a Maryland-licensed prescriber and a Maryland-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Maryland Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Massachusetts (2026)
Massachusetts telehealth GLP-1 care requires a Massachusetts-licensed prescriber and a Massachusetts-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Massachusetts Board of Registration in Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Michigan (2026)
Michigan telehealth GLP-1 care requires a Michigan-licensed prescriber and a Michigan-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Michigan Department of Licensing and Regulatory Affairs lookup, and the price floors that apply here like everywhere.
GLP-1s in Minnesota (2026)
Minnesota telehealth GLP-1 care requires a Minnesota-licensed prescriber and a Minnesota-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Minnesota Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Mississippi (2026)
Mississippi telehealth GLP-1 care requires a Mississippi-licensed prescriber and a Mississippi-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Mississippi Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Missouri (2026)
Missouri telehealth GLP-1 care requires a Missouri-licensed prescriber and a Missouri-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Missouri Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Montana (2026): Who Ships Here
Montana telehealth GLP-1 care requires a Montana-licensed prescriber and a Montana-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Montana Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Nebraska (2026)
Nebraska telehealth GLP-1 care requires a Nebraska-licensed prescriber and a Nebraska-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Nebraska Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Nevada (2026): Who Ships Here
Nevada telehealth GLP-1 care requires a Nevada-licensed prescriber and a Nevada-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Nevada State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in New Hampshire (2026)
New Hampshire telehealth GLP-1 care requires a New Hampshire-licensed prescriber and a New Hampshire-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New Hampshire Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in New Jersey (2026)
New Jersey telehealth GLP-1 care requires a New Jersey-licensed prescriber and a New Jersey-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New Jersey State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in New Mexico (2026)
New Mexico telehealth GLP-1 care requires a New Mexico-licensed prescriber and a New Mexico-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New Mexico Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in New York (2026)
New York telehealth GLP-1 care requires a New York-licensed prescriber and a New York-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New York State Education Department, Office of the Professions lookup, and the price floors that apply here like everywhere.
GLP-1s in North Carolina (2026)
North Carolina telehealth GLP-1 care requires a North Carolina-licensed prescriber and a North Carolina-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the North Carolina Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in North Dakota (2026)
North Dakota telehealth GLP-1 care requires a North Dakota-licensed prescriber and a North Dakota-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the North Dakota State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Ohio (2026): Who Ships Here
Ohio telehealth GLP-1 care requires a Ohio-licensed prescriber and a Ohio-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the State of Ohio Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Oklahoma (2026)
Oklahoma telehealth GLP-1 care requires a Oklahoma-licensed prescriber and a Oklahoma-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Oklahoma State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Oregon (2026): Who Ships Here
Oregon telehealth GLP-1 care requires a Oregon-licensed prescriber and a Oregon-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Oregon Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Pennsylvania (2026)
Pennsylvania telehealth GLP-1 care requires a Pennsylvania-licensed prescriber and a Pennsylvania-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Pennsylvania State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Rhode Island (2026)
Rhode Island telehealth GLP-1 care requires a Rhode Island-licensed prescriber and a Rhode Island-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Rhode Island Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in South Carolina (2026)
South Carolina telehealth GLP-1 care requires a South Carolina-licensed prescriber and a South Carolina-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the South Carolina Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in South Dakota (2026)
South Dakota telehealth GLP-1 care requires a South Dakota-licensed prescriber and a South Dakota-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the South Dakota State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Tennessee (2026)
Tennessee telehealth GLP-1 care requires a Tennessee-licensed prescriber and a Tennessee-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Tennessee Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Texas (2026): Who Ships Here
Texas telehealth GLP-1 care requires a Texas-licensed prescriber and a Texas-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Texas State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Utah (2026): Who Ships Here
Utah telehealth GLP-1 care requires a Utah-licensed prescriber and a Utah-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Utah Division of Professional Licensing lookup, and the price floors that apply here like everywhere.
GLP-1s in Vermont (2026): Who Ships Here
Vermont telehealth GLP-1 care requires a Vermont-licensed prescriber and a Vermont-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Vermont Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Virginia (2026)
Virginia telehealth GLP-1 care requires a Virginia-licensed prescriber and a Virginia-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Virginia Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Washington (2026)
Washington telehealth GLP-1 care requires a Washington-licensed prescriber and a Washington-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Washington Pharmacy Quality Assurance Commission lookup, and the price floors that apply here like everywhere.
GLP-1s in Washington, D.C. (2026)
D.C. telehealth GLP-1 care requires a D.C.-licensed prescriber and a D.C.-licensed pharmacy — both verifiable on the District's health-licensing portal. The footprint nuance most lists miss (Henry's '41 states' count is built from the 50 states, leaving D.C. to confirm), plus the price floors that apply here like everywhere.
GLP-1s in West Virginia (2026)
West Virginia telehealth GLP-1 care requires a West Virginia-licensed prescriber and a West Virginia-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the West Virginia Board of Pharmacy lookup, and the price floors that apply here like everywhere.
GLP-1s in Wisconsin (2026)
Wisconsin telehealth GLP-1 care requires a Wisconsin-licensed prescriber and a Wisconsin-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Wisconsin Pharmacy Examining Board lookup, and the price floors that apply here like everywhere.
GLP-1s in Wyoming (2026): Who Ships Here
Wyoming telehealth GLP-1 care requires a Wyoming-licensed prescriber and a Wyoming-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Wyoming State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Medicaid by state
Medi-Cal and GLP-1s in 2026
Effective January 1, 2026, Medi-Cal ended GLP-1 coverage for weight loss for adults 21 and older — Wegovy, Zepbound, and Saxenda came off the Contract Drug List for weight indications. What DHCS's own bulletins say still qualifies: diabetes, cardiovascular disease, kidney disease, the under-21 EPSDT path, appeals, and the cash reality.
The Medicaid GLP-1 Change Ledger
A running, dated record of state Medicaid GLP-1 weight-loss coverage changes: California's January 1 exit, North Carolina's December 12 reinstatement, the Utah pilot's June 30 end, Massachusetts's July 1 end, and the KFF count falling from sixteen to thirteen to roughly eleven — with each entry's evidentiary status labeled.
Delaware Medicaid and GLP-1s in 2026
Delaware covers Wegovy, Zepbound, and Saxenda for weight loss with prior authorization — no restriction wave, no pending bill, no drama on the record. What that stability is worth, what the PA still requires, and what to verify anyway.
Kansas Medicaid and GLP-1s in 2026
KanCare covers Wegovy, Zepbound, and Saxenda under restricted prior-authorization criteria — a severe-obesity pathway plus a separate Wegovy cardiovascular pathway that is not the only route in. What the tracker verification establishes, what it doesn't, and the two-door strategy for Kansas enrollees.
Michigan Medicaid and GLP-1s in 2026
Effective January 1, 2026, Michigan Medicaid restricted GLP-1 weight-loss coverage to the strictest standard of any covering state: morbid obesity, documented failure of other interventions, preferred-agent step therapy, and bariatric-surgery avoidance — per MDHHS notification L 25-73. What survived: diabetes coverage, the cardiovascular and sleep-apnea doors, and the under-21 path.
Minnesota Medicaid and GLP-1s in 2026
Minnesota's Medical Assistance program covers GLP-1s for weight loss with prior authorization and appears on every 2026 covering-state count — but a bill to prohibit that coverage reached committee in March 2026 before legislators delayed action. The record, the cost pressure behind the bill, and what to watch.
Mississippi Medicaid and GLP-1s in 2026
Mississippi covers Wegovy, Zepbound, and Saxenda for weight loss with prior authorization. In 2026 the legislature passed SB 2867 to expand the benefit; the governor vetoed it on fiscal grounds — and existing coverage continued unchanged. The record, the distinction that matters, and the standing doors.
Missouri Medicaid and GLP-1s in 2026
Missouri appears on every 2026 covering-state count, and the sourced state-by-state record marks it as an addition — a state that adopted GLP-1 weight-loss coverage while California, Pennsylvania, and others were cutting it. What's verified, what still needs the drug-list confirmation, and how to use it.
NC Medicaid and GLP-1s in 2026
North Carolina Medicaid covered GLP-1s for weight management from August 2024, paused it in 2025, then reinstated coverage effective December 12, 2025 under the Governor's directive — reverting to the September 30, 2025 criteria across Medicaid Direct and Managed Care. The bulletin record, the criteria, and the doors that never closed.
Rhode Island Medicaid and GLP-1s in 2026
Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss effective October 1, 2026; coverage continues for type 2 diabetes and other FDA-approved indications. The dated record and what enrollees can still do.
Tennessee Medicaid and GLP-1s in 2026
TennCare appears as a covering state on every 2026 count with prior authorization required — and the tracker record flags the specific drug list for verification. What's solid, what needs the one call, and the full door map for Tennessee enrollees.
Virginia Medicaid and GLP-1s in 2026
Virginia Medicaid covers GLP-1s for weight loss with some of the country's strictest criteria — and tightened them mid-2026. The DMAS bulletin's BMI-40 (or 35-plus-two-conditions) standard, the service-authorization form's step therapy and five-percent renewal rule, age minimums by drug, and what existing authorizations keep.
Wisconsin Medicaid and GLP-1s in 2026
Wisconsin appears on every 2026 covering-state count for Medicaid GLP-1 weight-loss coverage, and ForwardHealth's own documents spell out the mechanics: preferred agents without PA but diagnosis-restricted on every prescription and claim, non-preferred agents under revised PA criteria with 183-day initial approvals. One directory claims no obesity benefit exists — here is the honest record.
Clinical and practical
Exercising on GLP-1s: Fueling Training in a Deficit Without
The medication creates the deficit; training decides what the lost weight is made of. How to fuel workouts when appetite is suppressed — protein anchors, deliberate carbs around sessions, hydration math — plus the dizziness rule and the program that protects muscle.
GLP-1s and Antidepressants
SSRIs, SNRIs, and most antidepressants have no direct pharmacokinetic conflict with GLP-1s — the real considerations are additive early nausea, appetite and weight interplay with psych-med side effects, and mood monitoring during major weight change. The map, minus the alarm.
GLP-1s and Birth Control: The Tirzepatide Rule Every Label
Tirzepatide's label carries a specific instruction: patients on oral contraceptives should use barrier backup for four weeks after starting and after each dose escalation — because delayed gastric emptying can reduce pill absorption exactly when exposure changes. The rule, the mechanism, and the semaglutide contrast.
GLP-1s and Levothyroxine: The Absorption Question
Slowed gastric emptying can change how oral medications absorb — and levothyroxine, famously fussy about absorption, is the one thyroid patients ask about most. The mechanism, the label context, the empty-stomach rules that don't change, and the follow-up TSH that settles it.
GLP-1s and Metformin Together
Metformin plus a GLP-1 is the default stack in metabolic medicine — no meaningful pharmacokinetic conflict, complementary mechanisms, additive GI effects to manage. What each does, why prescribers keep both, and the practical rules of running them together.
GLP-1s Before Surgery: The Hold-a-Week Guidance
Anesthesiology guidance since 2023 directs holding weekly GLP-1s for a week before elective procedures — slowed gastric emptying means food can remain in the stomach past standard fasting windows, an aspiration risk under anesthesia. The rule, the reasons, and the conversation to have before any procedure.
GLP-1s and Blood Pressure Medications
Weight loss lowers blood pressure — which means yesterday's correct antihypertensive dose becomes tomorrow's excessive one, showing up as dizziness, fatigue, and falls that get blamed on the GLP-1. The monitoring rhythm, the symptoms that are actually numbers, and the deprescribing win hiding inside.
GLP-1 Constipation: The Fix Ladder That Works
Slowed motility plus smaller food volume makes constipation the class's most persistent complaint — and its most fixable, with a ladder that starts at fluids and fiber and ends at clinician-guided options. The protocol, the timeline, and the rare-but-real blockage signs.
Dehydration on GLP-1s: The Suppressed-Thirst Trap and the
Appetite suppression takes thirst down with it — quietly, which is why dehydration underlies half the class's 'side effects': headaches, fatigue, dizziness, constipation. The deliberate-intake protocol, when electrolytes matter, and the GI-illness escalation plan.
Fatigue on GLP-1s: The Deficit Explanation
Early-phase tiredness usually has boring causes — a large calorie deficit, quiet dehydration, protein shortfall, disrupted sleep — each fixable. The triage order, the adaptation timeline, and the lab panel worth running when fatigue persists past it.
GLP-1s and Fatty Liver Disease
A quarter to a third of US adults carry MASLD, and this drug class now has real liver evidence: semaglutide's phase-3 MASH trial resolved steatohepatitis in roughly twice the placebo rate, and 2026 network meta-analysis work places tirzepatide among effective fibrosis interventions. The honest map of a fast-moving field.
GLP-1s for Men: Testosterone
Men arrive with a specific cluster — visceral fat, sleep apnea, suppressed testosterone, cardiac risk — and major weight loss moves every item on it. What commonly improves and why, the muscle-preservation stakes, and the screening conversations worth having at intake.
GLP-1s for Women: The Side-Effect Data
Women report GI side effects at somewhat higher rates in trial and real-world data — and one label instruction is women-specific and widely missed: tirzepatide reduces oral contraceptive reliability during startup and escalations, and the label says add a backup method. The evidence, the four-week backup rule, the 'Ozempic babies' mechanism, and pre-pregnancy planning.
The GLP-1 Glossary: Every Term That Gates Your Price
Sixty-four working definitions — 503A vs 503B, BUD, COA, EPSDT, MACE, MASH, PA, PDL, rankable, salt forms, SELECT, SURMOUNT, titration, units-to-mg and the rest — each written to answer the question the term actually gates in the real market.
GLP-1s and Hair Loss: The Telogen Effluvium Explanation
Hair shedding a few months into treatment is usually telogen effluvium — the follicle cycle's stereotyped response to rapid weight loss, not a direct drug effect — and it's typically temporary. The mechanism, the timeline, the labs worth checking, and the nutrition that matters.
GLP-1s and Heart Health: What SELECT Proved
The SELECT trial — 17,600 adults with cardiovascular disease and overweight, no diabetes — showed semaglutide cut major cardiac events by about 20%, earning Wegovy a cardiovascular indication. What that means, who it applies to, and the second insurance door it opened.
Injection Site Reactions: Normal, Annoying, or Infected
Most injection-site events are cosmetic and technique-responsive: small redness, bruises, itching, the occasional lump. The rotation and technique that prevent them, the buckets that classify them, and the spreading-redness-warmth-fever cluster that means call.
GLP-1 Injection Technique
The label-standard basics — abdomen, thigh, or upper arm; rotate sites; subcutaneous, any time of day — plus the part compounded programs assume you'll figure out: drawing from a multi-dose vial, air bubbles, needle hygiene, and sharps disposal. What your pharmacy should teach, and the errors the FDA's report file exists because of.
GLP-1s With Insulin or Sulfonylureas
GLP-1s don't cause hypoglycemia — until they're stacked on insulin or a sulfonylurea, where the labels themselves advise considering dose reductions at initiation. Why the combination lowers sugar too well, the symptoms to know cold, and the coordination rule that makes it safe.
Intermittent Fasting on a GLP-1
The drug already does what most people use fasting for — so stacking them is often under-fueling with extra steps. When IF still earns a place (structure, preference), the protein and hydration math it must survive, and the insulin/sulfonylurea case where it's genuinely unsafe without supervision.
GLP-1s and Lithium: The Narrow-Window Interaction That Made
Lithium's tiny therapeutic window meets the GLP-1 era's fluid and intake changes: a 2026 case report documented toxicity requiring hemodialysis in a previously stable patient after starting tirzepatide. The mechanism, the monitoring protocol that prevents it, and the coordination rule with no exceptions.
GLP-1 Microdosing in 2026
Gala sells microdosing at $149, Enhance MD tirzepatide microdosing at $169, and the search volume keeps climbing — but 'microdosing' has no trial behind it. What the tiers actually are, the three arguments made for them, what the dose-response data really shows, and the questions to ask before paying for less.
Missed a GLP-1 Dose? The 4-Day and 5-Day Rules
The labels are specific: a missed tirzepatide dose can be taken within 4 days (96 hours), semaglutide within 5 — after that, skip and resume; never double. The day-change minimums, what happens after two or more missed weeks, the LillyDirect 45-day pricing trap that stacks on top, and the restart conversation.
Muscle Loss on GLP-1s: What the DXA Data Shows
In body-composition substudies, roughly a quarter to two-fifths of GLP-1 weight loss was lean mass — normal for major weight loss, and defensible. Why lean mass is the variable that decides your maintenance metabolism, the protein and resistance-training levers with actual evidence, and how to tell if you're losing the wrong kind of weight.
GLP-1 Nausea: Every Remedy That Actually Helps
Nausea is the class's signature side effect and its most manageable: meal mechanics do most of the work, a few home remedies genuinely help, prescription options exist for the hard cases, and the pattern itself — escalation echoes that fade — is half the reassurance. The complete toolkit.
GLP-1s After 65: Sarcopenia Stakes
Older adults get real benefit from this class — and face its risks with less margin: muscle loss lands on age-depleted reserves, dehydration and dizziness carry fall stakes, and every weight-sensitive medication needs re-dosing. The geriatric-literate protocol.
GLP-1s and PCOS: What the Evidence Supports
No GLP-1 carries a PCOS indication — but PCOS's metabolic core (insulin resistance, weight-responsive ovulation) sits squarely in the class's mechanism, and clinicians increasingly use them off-label. The honest evidence review, the metformin question, and the contraception warning that matters more here than anywhere.
GLP-1s for Prediabetes: The Reversion Evidence
In the weight-loss trials, the large majority of participants with prediabetes reverted to normal glucose regulation on treatment — a striking, consistent finding without an FDA indication or, usually, insurance coverage behind it. The evidence, the DPP context, and the decision most prediabetic buyers actually face.
GLP-1 Side Effects A to Z
Every documented tirzepatide and semaglutide side effect in one alphabetical reference — from appetite changes to vomiting — with label frequencies, the boxed warning, the symptoms that mean stop-and-call, and links to the full guide on each.
Sulfur Burps and Reflux on GLP-1s
The infamous rotten-egg burps and new-onset reflux share one cause — food sitting longer in a slowed stomach — and mostly one solution set: smaller, lower-fat meals, upright time after eating, and titration patience. The mechanism, the fix list, and the red flags that mean call.
GLP-1s for Type 2 Diabetes
Before the weight-loss era, these were diabetes drugs — and for T2D they remain first-tier: tirzepatide cut HbA1c by roughly 1.9–2.5 points across SURPASS with 7–12 kg weight loss. What the diabetes indication changes for treatment and, decisively, for insurance.
Hitting GLP-1 Protein Targets on a Vegetarian or Vegan Diet
1.2–1.6 g/kg of protein on a suppressed appetite is hard; doing it from plants adds a volume problem and a leucine question — both solvable with the right staples. The vegetarian playbook: the dense sources, the per-meal threshold, and the B12 note that's actually real here.
Vials, Units, and Reconstitution Math
The FDA's adverse-event record for compounded GLP-1s traces overwhelmingly to at-home dosing errors — units read off the wrong concentration, reconstitution volumes guessed, milligrams and milliliters conflated. The three numbers on every vial, the one formula that converts between them, worked examples at real concentrations, and the checks that catch an error before it's injected.
GLP-1s and Breastfeeding: What the Absence of Data Means in
No adequate human data establishes safety of semaglutide or tirzepatide during lactation — which is why standard guidance runs conservative: these medications are generally deferred while breastfeeding, and compounded versions add unknowns on top of unknowns. The honest page, and the postpartum planning that actually helps.
How to Store GLP-1 Medications
Every GLP-1 lives in the refrigerator by default — with brand-specific room-temperature allowances the labels spell out (Wegovy 28 days before use, Ozempic 56 days in-use, Zepbound and Mounjaro 21 days) and one absolute: frozen product is discarded, never thawed and used. The storage map, including the compounded rule.
Semaglutide 0.25 mg: The Non-Therapeutic Starter
0.25 mg is explicitly a tolerance dose — the label calls it non-therapeutic for glycemic control, and weight effects are incidental. What the first four weeks are for, why judging results here is a category error, and the intro-pricing economics that target exactly this phase.
Semaglutide 0.5 mg: First Working Dose
0.5 mg wears two hats: a legitimate maintenance dose on the diabetes label (Ozempic) and the first real rung on the weight-loss climb to 2.4. What each pathway expects here, the modest-but-real effects, and the four-week evaluation.
Semaglutide 1.7 mg: The Last Step Before Full Dose
1.7 mg exists on the weight-management ladder specifically — the four-week staging dose before 2.4, above the diabetes label's ceiling. What the penultimate step is for, the hold-here question, and the mechanics of the final climb.
Semaglutide 1 mg: The Ozempic Workhorse and the Weight
1 mg is the diabetes label's classic maintenance dose — the SURPASS-2 comparator, the dose most 'Ozempic' prescriptions mean — and the weight ladder's halfway mark. What each identity expects, the head-to-head context, and the climb remaining.
Semaglutide 2.4 mg: The Full Dose
2.4 mg is where semaglutide's evidence lives: 14.9% average loss at 68 weeks in STEP-1, the 20% cardiovascular risk reduction in SELECT, the head-to-head result against tirzepatide. The full-dose facts, maintenance at the top, and the 7.2 tier above it.
Semaglutide and Alcohol: What the Craving Research Actually
'Semaglutide impact on drinking' is a breakout search for a reason: trial and real-world evidence increasingly shows reduced alcohol craving and intake on GLP-1s. The research read honestly, the practical effects of drinking during treatment, who needs extra caution, and what none of this licenses.
Semaglutide Units to Mg: Why There Is No Universal Dosage
Searches for a compounded semaglutide dosage chart are up 200% — and every universal chart is wrong, because syringe units measure volume while your dose is in milligrams, and the conversion depends entirely on your vial's concentration. The actual math, the standard titration schedule from the FDA label, and the questions that keep you safe.
What Happens When You Stop a GLP-1
The withdrawal trials are unambiguous: stop tirzepatide and average regain runs about 14% of body weight within a year; stop semaglutide and roughly two-thirds of lost weight returns. What the trials actually did, why regain happens, the strategies with evidence behind them, and how to price a multi-year reality honestly.
Tirzepatide 10 mg: The 19.5% Arm
10 mg is the middle studied maintenance dose and arguably the efficiency point: 19.5% average loss at 72 weeks — 1.4 points shy of 15 mg with meaningfully easier tolerability. The arm's numbers, who lands here, and the hold-versus-max decision.
Tirzepatide 12.5 mg: The Last Step Before Max
Like 7.5, the 12.5 mg dose is labeled but wasn't a SURMOUNT-1 arm — it's the mandated staging step to 15 mg and a legitimate place to stop. The between-arms logic at the top of the ladder, where the marginal averages are smallest.
Tirzepatide 15 mg: The Maximum Dose
15 mg is tirzepatide's ceiling: 20.9% average loss at 72 weeks in SURMOUNT-1, the strongest studied result in the approved class — carrying the ladder's fullest side-effect load and the plateau question with nowhere higher to go. The top rung, examined.
Tirzepatide 2.5 mg: The Starter Dose
2.5 mg is tirzepatide's initiation dose: four weeks of tolerance-building, not a maintenance target. What the label says it's for, why weight results are modest by design, the $299 brand rung and $199-intro economics, and the escalation ahead.
Tirzepatide 5 mg: The First Maintenance Dose
5 mg is where tirzepatide's studied results begin: 15.0% average loss at 72 weeks in SURMOUNT-1 — a full maintenance dose many patients never need to leave. What the arm showed, who stays here, the $399 brand rung, and the escalate-or-hold decision.
Tirzepatide 7.5 mg: The In-Between Dose
7.5 mg wasn't a SURMOUNT-1 arm — it's the labeled step between the 15% and 19.5% doses, where many patients land clinically. How to reason about an unstudied-but-labeled dose, the escalation echo, and the $449 price threshold it crosses.
Tirzepatide, Gallbladder Disease, and Pancreatitis
Both risks sit on the label; neither is common. Gallstone events tracked in the low single digits in trials — largely a rapid-weight-loss effect any method shares — and pancreatitis remains rare with a symptom signature worth memorizing. The mechanisms, the honest rates, who carries extra risk, and the exact symptoms that mean stop and call.
Does Tirzepatide Cause Headaches? What the Trials Recorded
Headache shows up in tirzepatide's trial data at modest single-digit rates — real, but usually downstream of three fixable things: dehydration from GI effects, an aggressive calorie drop, and abandoned caffeine. The evidence, the fixes, and the headache patterns that warrant a call instead of a glass of water.
Tirzepatide Plateaus: Why the Scale Stops
Every weight-loss curve flattens — SURMOUNT-1's own averages were leveling by trial's end near 21%. Why plateaus are physiology rather than failure, how to tell a true plateau from a two-week stall, and the five real options: adherence audit, dose headroom, lifestyle re-anchor, class switch, or declaring victory.
Tirzepatide Side Effects, Week by Week
In the trials, roughly a quarter to a third of tirzepatide patients had nausea and about one in five had diarrhea — overwhelmingly mild to moderate, clustered around dose escalations, fading with time. The realistic week-by-week timeline, the management that works, and the specific symptoms that mean call your clinician now.
Tirzepatide for Sleep Apnea
Since December 2024, Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — the SURMOUNT-OSA trials cut apnea events by roughly 25–30 per hour versus about 5 on placebo, with a large share reaching remission-range severity. What the indication changes, including for insurance.
Traveling With GLP-1s: TSA Rules
Injectable medication travels legally and easily — needles and all — in carry-on luggage, with an insulated pack solving the cold chain and the weekly schedule shrugging off time zones. The complete protocol: security, packing, international paperwork, and what never goes in checked baggage.